Olysio

J&J discloses DOJ investigations into marketing, advisory practices
J&J discloses DOJ investigations into marketing, advisory practices
BioPharma Dive
JNJ
DOJ
drug marketing
Remicade
Olysio
Simponi
Stelara
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
J&J advances through PhII with a promising hep C triple and 100% cure rate
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
JNJ
hepatitis C
clinical trials
odalasvir
AL-335
Olysio
Achillion
Flag link:
Competition drives down sales of J&J's Olysio
Competition drives down sales of J&J's Olysio
Medical Marketing and Media
JNJ
Olysio
earnings
Flag link:
The Worst Johnson & Johnson Headlines in 2015
The Worst Johnson & Johnson Headlines in 2015
Motley Fool
JNJ
drug pricing
Olysio
Flag link:
Johnson & Johnson Tells Gilead Sciences "Game On"
Johnson & Johnson Tells Gilead Sciences "Game On"
Motley Fool
JNJ
Gilead Sciences
hepatitis C
Olysio
Incivek
Harvoni
Sovaldi
Flag link:
J&J Wins U.S. Approval for Hepatitis C Combo With Gilead
J&J Wins U.S. Approval for Hepatitis C Combo With Gilead
Bloomberg
JNJ
FDA
Gilead Sciences
hepatitis C
Olysio
Flag link:
If It’s Bad For Merck, It’s Good For Gilead
If It’s Bad For Merck, It’s Good For Gilead
Barron's
Merck
Gilead Sciences
hepatitis C
Sovaldi
JNJ
Olysio
Flag link:
3 Drugs Critical to Johnson & Johnson's Future
3 Drugs Critical to Johnson & Johnson's Future
Motley Fool
JNJ
Olysio
Zytiga
Invega Sustenna
Xarelto
Stelara
Flag link:
What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
Motley Fool
JNJ
Gilead Sciences
Olysio
hepatitis C
Sovaldi
Flag link:
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Motley Fool
JNJ
Olysio
earnings
biosimilars
Flag link:
Do This Drug's Sales Make J&J a Hepatitis C Powerhouse?
Do This Drug's Sales Make J&J a Hepatitis C Powerhouse?
Motley Fool
JNJ
hepatitis C
Olysio
Flag link:
Is This Johnson & Johnson's Worst Nightmare?
Is This Johnson & Johnson's Worst Nightmare?
Motley Fool
JNJ
Zytiga
Medivation
Xtandi
Olysio
Gilead Sciences
Sovaldi
Flag link:
A Primer On The Hepatitis C Market
A Primer On The Hepatitis C Market
Yahoo/Investors Business Daily
hepatitis C
Gilead
Sovaldi
Merck
Victrelis
Incivek
Vertex Pharmaceuticals
Olysio
JNJ
AbbVie
Indenix
Bristol-Myers Squibb
Flag link:
J&J /Gilead HCV Combo Drug Filed
J&J /Gilead HCV Combo Drug Filed
Yahoo/Zacks.com
JNJ
Gilead Sciences
hepatitis C
Olysio
Sovaldi
Flag link:
Drugs That Will Help Johnson & Johnson Grow By 5% In 2014
Drugs That Will Help Johnson & Johnson Grow By 5% In 2014
Forbes
JNJ
Remicade
Olysio
Velcade
Zytiga
Flag link:
J&J-Medivir Hepatitis C Drug Recommended by EU Regulator
J&J-Medivir Hepatitis C Drug Recommended by EU Regulator
Bloomberg
JNJ
hepatitis C
Europe
Medivir
Olysio
Flag link:
Prices of new hepatitis C drugs are tough to swallow for insurers
Prices of new hepatitis C drugs are tough to swallow for insurers
LA Times, CA
insurance
hepatitis C
Sovaldi
Gilead Sciences
Olysio
JNJ
Janssen
Flag link:
What Is Johnson & Johnson's Opportunity In Hepatitis C Market?
What Is Johnson & Johnson's Opportunity In Hepatitis C Market?
Forbes
JNJ
hepatitis C
Olysio
Flag link:
What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
Seeking Alpha
JNJ
Gilead Sciences
hepatitis C
sofosbuvir
Olysio
AbbVie
Bristol-Myers Squibb
Merck
Flag link: